Next Article in Journal
Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma
Previous Article in Journal
The Physician’s Achilles Heel—Surviving an Adverse Event
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 6
10.3747/co.26.4861
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada

by
Hagen Kennecke
1,*,
S. Berry
2,
J. Maroun
3,
P. Kavan
4,
N. Aucoin
5,
F. Couture
6,
M. Poulin-Costello
7 and
B. Gillesby
7
1
Virginia Mason Hospital and Seattle Medical Center, Seattle, WA 98101, USA
2
Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
3
Medical Oncology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
4
Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC, Canada
5
Hôpital de la Cité-de-la-Santé, Laval, QC, Canada
6
Centre hospitalier universitaire de Québec, Quebec City, QC, Canada
7
Amgen Canada, Inc., Mississauga, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(6), 748-754; https://doi.org/10.3747/co.26.4861
Submission received: 2 September 2019 / Revised: 8 October 2019 / Accepted: 8 November 2019 / Published: 1 December 2019

Abstract

Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The objectives of the present study were to describe, for patients with mcrc, attrition across lines of systemic therapy, patterns of therapy and their timing, and KRAS status. Methods: A retrospective chart review at 6 Canadian academic centres included sequential patients who were diagnosed with mcrc from 1 January 2009 onward and who initiated first-line systemic treatment for mcrc between 1 January and 31 December 2009. Death was included as a competing risk in the analysis. Results: The analysis included 200 patients who started first-line therapy. The proportions of patients who started second-, third-, and fourth-line systemic therapy were 70%, 30%, and 15% respectively. Chemotherapy plus bevacizumab was the most common first-line combination (66%). The most common first-line regimen was folfiri plus bevacizumab. KRAS testing was performed in 103 patients (52%), and 38 of 68 patients (56%, 19% overall) with confirmed KRAS wild-type tumours received an epidermal growth factor receptor inhibitor (egfri), which was more common in later lines. Most KRAS testing occurred after initiation of second-line therapy. Conclusions: In the modern treatment era, a high proportion of patients receive at least two lines of therapy for mcrc, but only 19% receive egfri therapy. Earlier KRAS testing and therapy with an egfri might allow a greater proportion of patients to access all 5 active treatment agents.
Keywords: Treatment patterns; epidermal growth factor inhibitor; KRAS testing; anti-vascular growth factor agents; chemotherapy Treatment patterns; epidermal growth factor inhibitor; KRAS testing; anti-vascular growth factor agents; chemotherapy

Share and Cite

MDPI and ACS Style

Kennecke, H.; Berry, S.; Maroun, J.; Kavan, P.; Aucoin, N.; Couture, F.; Poulin-Costello, M.; Gillesby, B. A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada. Curr. Oncol. 2019, 26, 748-754. https://doi.org/10.3747/co.26.4861

AMA Style

Kennecke H, Berry S, Maroun J, Kavan P, Aucoin N, Couture F, Poulin-Costello M, Gillesby B. A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada. Current Oncology. 2019; 26(6):748-754. https://doi.org/10.3747/co.26.4861

Chicago/Turabian Style

Kennecke, Hagen, S. Berry, J. Maroun, P. Kavan, N. Aucoin, F. Couture, M. Poulin-Costello, and B. Gillesby. 2019. "A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada" Current Oncology 26, no. 6: 748-754. https://doi.org/10.3747/co.26.4861

APA Style

Kennecke, H., Berry, S., Maroun, J., Kavan, P., Aucoin, N., Couture, F., Poulin-Costello, M., & Gillesby, B. (2019). A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada. Current Oncology, 26(6), 748-754. https://doi.org/10.3747/co.26.4861

Article Metrics

Back to TopTop